Navigation Links
Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
Date:10/17/2011

SAN DIEGO, Oct. 17, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM),  launched its noninvasive proprietary MaterniT21 laboratory developed  test (LDT). The MaterniT21 LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome. The test is now available to physicians upon request in 20 major metropolitan regions across the United States.

A clinical validation study leading to the introduction of the MaterniT21 LDT has been published in the journal Genetics in Medicine.  The results of the multi-center study demonstrated high accuracy, detecting nearly all (99.1%) positive cases of fetal Trisomy 21 with a very low false positive rate. The full results of the multi-center study can be found online at http://journals.lww.com/geneticsinmedicine/.

"As we advance our role in developing and commercializing prenatal diagnostics, we believe this LDT will be a welcomed addition to the testing currently available to the prenatal and maternal care community," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. "We believe that the MaterniT21 LDT will provide physicians and their patients with critical new information to help them make better informed decisions about the patients' healthcare and pregnancies."

The MaterniT21 test is indicated for use in pregnant women at high-risk for carrying a fetus with Down syndrome and can accurately test maternal blood as early as 10 weeks of gestation. In the United States, there are an estimated 750,000 such high-risk pregnancies each year.

"The results of this large clinical validation study are extremely promising and t
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. SEQUENOM Announces Launch of MassARRAY Compact 96 System
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. Sequenom Appoints Two New Board Members
6. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom to Present at Two Financial Conferences in September
9. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
(Date:3/26/2015)... NJ (PRWEB) March 26, 2015 WriteResult, ... partnered with researchers from Yale University’s School of Public ... by study participants during a 4 month-long project. The ... of providing low income families with free access to ... habits and diet-related health concerns like high blood pressure, ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... pervasive uptake of smartphones have fuelled social media ... population being currently engaged in social networking. Insurance ... exhaustively to communicate with clients and promote a ... the globe over are increasingly exploiting social networking ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3
... Fla., April 14 Phlo Corporation,(Pink Sheets: PHCP) ... stock certificates are negotiable in connection with,market transactions ... current,position in Phlo common stock. This clarification was ... number of brokers and clearing firms,will not negotiate ...
... in the second quarter of 2008 ... ... Ardea,Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data ... compounds demonstrating potent,activity against the human-immunodeficiency virus (HIV), including NNRTI-,resistant strains, with ...
... basis of blood-based ColonSentry(TM) test -, TORONTO, ... company focused on developing blood-based biomarker tests for ... today reported,positive performance results from a large validation ... of a patient,s current risk for,colorectal cancer. This ...
Cached Biology Technology:Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 3GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... An experimental drug that blocks two points of ... of ovarian cancer cells and significantly increases survival in ... Jonsson Comprehensive Cancer Center has found. The drug, ... that have become resistant to the conventional treatment with ...
... use of stored blood during transfusions may cause adverse effects ... funded a number of research projects to examine the safety ... blood on respiratory gases. These papers discussing potential adverse effects ... transfusion are now available online in TRANSFUSION , a ...
... a novel approach that works around the gene defect in Wiskott-Aldrich ... signaling pathway to significantly improve immune function in a 13-year-old boy ... provides a proof-of-principle that immunotherapy, which harnesses elements of the body,s ... deadly disorder. ...
Cached Biology News:Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth 2Safety of stored blood among chief concerns for transfusion medicine community 2Novel therapy improves immune function in teen with rare disease 2
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
Biology Products: